East Asia Pharmaceutical announced that it is expected to achieve net profit for the first half year of 2026 with a loss of 110 million yuan to a loss of 120 million yuan, and net profit for the same period last year of 30.283 million yuan. During the reporting period, the main reason for the pre-loss in the company's performance: on the revenue side, beta-lactam antimicrobials experienced general inventory removal in the industry, due to the relatively immediate demand for antimicrobial-related drugs, which led to a recovery in the sales scale of the company's related products. However, due to factors such as lower domestic procurement prices, industry-related policies, and increased market competition, the price pressure on the product side is still high. Coupled with the increase in the amount of stoppage losses due to insufficient operating rates of some production lines in the context of the company's implementation of inventory removal strategies, some of the company's products are under pressure to reduce gross margin.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.